The ideal nanocarrier size depends on the application and the required drug loading. Typically, nanocarriers should be smaller than 400 nm to prevent mononuclear phagocytes from being recognized and cleared by the immune system. Nanocarrier size affects in vivo distribution, with smaller particles having lower liver uptake. For most of these applications, the nanocarrier should be smaller than 200 nm, ideally ≤100 nm, to improve the permeability and retention (EPR) effect and thus extravasation of the drug into the tumor. If the size is <100nm, there are reports of higher rates of drug entry into cells and faster lymphatic transport. It should be noted that as the size decreases, the loading capacity also decreases, so more NP may be required to ensure the therapeutic effect. In addition to nanocarrier size, its composition, shape, and surface charge can also influence release behavior and accumulation.
We use cookies to ensure the website functions properly and, where permitted, to improve your experience. You can manage your preferences at any time in Settings. Learn more in our Cookie Policy.
Shall we send you a message when we have discounts available?
Remind me later
Thank you! Please check your email inbox to confirm.
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.